ArticleChinese medical journal pulmonary and critical care medicine2023
TIMP-1 and its potential diagnostic and prognostic value in pulmonary diseases.
Article in Chinese medical journal pulmonary and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Review
- Current Insights into Clinical, Molecular, and Therapeutic Approaches to Acute Respiratory Distress Syndrome.Medical sciences (Basel, Switzerland) · 2026Review
- Elevated MMP2 expression in fibrotic interstitial lung disease: a potential biomarker for assessment of disease severity.BMC pulmonary medicine · 2026Article
- A narrative review of the early diagnosis and treatment of idiopathic pulmonary fibrosis with lung cancer.Journal of thoracic disease · 2025Review
- Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits.Respiratory research · 2025Review
- Synergistic Neuroprotection of Artesunate and Tetramethylpyrazine in Ischemic Stroke, Mechanisms of Blood-Brain Barrier Preservation.International journal of molecular sciences · 2025Article
- Analysis of Stratifin Expression and Proteome Variation in a Rat Model of Acute Lung Injury.Journal of proteome research · 2025Article
- Innovations in heart failure management: The role of cutting-edge biomarkers and multi-omics integration.Journal of molecular and cellular cardiology plus · 2025Review
- Human hypofunctional NCF1 variants promote pulmonary fibrosis in the bleomycin-induced mouse model and patients with systemic sclerosis via expansion of SPP1Annals of the rheumatic diseases · 2025Article
- PDGFRα-positive cell-derived TIMP-1 modulates adaptive immune responses to influenza A viral infection.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- Hyaluronan in the pathogenesis of lung fibrosis associated to autoimmune pulmonary alveolar proteinosis (aPAP).Frontiers in medicine · 2025Article
- Albendazole ameliorates aerobic glycolysis in myofibroblasts to reverse pulmonary fibrosis.Journal of translational medicine · 2024Article
- Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2.Cell reports. Medicine · 2024Article
- Estrogen-dependent gene regulation: Molecular basis of TIMP-1 as a sex-specific biomarker for acute lung injury.Physiological reports · 2024Article
- Exploring Molecular Mechanisms and Biomarkers in COPD: An Overview of Current Advancements and Perspectives.International journal of molecular sciences · 2024Review
- Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction.Chinese medical journal pulmonary and critical care medicine · 2024Article
- The evaluation of the MMP-2/TIMP-1 ratio in peptic ulcer and its association with refractory helicobacter pylori infection.BMC gastroenterology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Tissue inhibitors of metalloproteases (TIMPs) have caught the attention of many scientists due to their role in various physiological and pathological processes. TIMP-1, 2, 3, and 4 are known members of the TIMPs family. TIMPs exert their biological effects by, but are not limited to, inhibiting the activity of metalloproteases (MMPs). The balance between MMPs and TIMPs is critical for maintaining homeostasis of the extracellular matrix (ECM), while the imbalance between MMPs and TIMPs can lead to pathological changes, such as cancer. In this review, we summarized the current knowledge of TIMP-1 in several pulmonary diseases namely, acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), pneumonia, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and pulmonary fibrosis. Considering the potential of TIMP-1 serving as a non-invasive diagnostic and/or prognostic biomarker, we also reviewed the circulating TIMP-1 levels in translational and clinical studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.